| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.66▼ | 1.65▼ | 1.65▼ | 1.82▼ | 1.98▼ |
| MA10 | 1.67▼ | 1.70▼ | 1.76▼ | 1.95▼ | 2.08▼ |
| MA20 | 1.77▼ | 1.82▼ | 1.86▼ | 2.05▼ | 2.17▼ |
| MA50 | 1.92▼ | 1.97▼ | 2.00▼ | 2.12▼ | 1.16▲ |
| MA100 | 2.02▼ | 2.07▼ | 2.13▼ | 2.18▼ | 1.03▲ |
| MA200 | 2.15▼ | 2.14▼ | 2.13▼ | 1.27▲ | 1.55▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.005▼ | -0.013▼ | -0.025▼ | -0.051▼ | -0.119▼ |
| RSI | 33.641▼ | 31.038▼ | 28.479▼ | 24.665▼ | 46.627▼ |
| STOCH | 18.777▼ | 9.141▼ | 6.180▼ | 14.806▼ | 29.108 |
| WILL %R | -96.970▼ | -96.970▼ | -97.260▼ | -85.938▼ | -91.892▼ |
| CCI | -85.972 | -78.750 | -101.570▼ | -219.102▼ | -225.631▼ |
|
IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site
Wednesday, October 29, 2025 05:24 AM
IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, today announced that The Ohio State ...
|
|
Monday, October 27, 2025 05:07 AM
INB-619 demonstrated equivalent efficacy to the FDA approved, commercial T Cell Engagers (TCE) compounds, blinatumomab and mosunetuzumab, with ...
|
|
Monday, October 13, 2025 07:56 AM
Mizuho lowered the firm’s price target on IN8bio (INAB) to $4 from $60 and keeps an Outperform rating on the shares. The firm continues to believe in IN8bio’s INB-100 program but adjusted the price ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 05/11/25 | 1.63 | 1.70 | 1.60 | 1.63 | 29,299 |
| 04/11/25 | 1.96 | 2.14 | 1.54 | 1.65 | 276,500 |
| 03/11/25 | 1.95 | 1.95 | 1.82 | 1.88 | 68,500 |
| 31/10/25 | 1.97 | 2.02 | 1.92 | 1.95 | 95,900 |
| 30/10/25 | 2.00 | 2.049 | 1.95 | 1.99 | 71,500 |
| 29/10/25 | 2.08 | 2.10 | 1.98 | 2.00 | 78,800 |
| 28/10/25 | 2.12 | 2.14 | 2.06 | 2.10 | 47,578 |
| 27/10/25 | 2.12 | 2.15 | 2.04 | 2.10 | 181,500 |
| 24/10/25 | 2.10 | 2.16 | 2.07 | 2.14 | 14,700 |
| 23/10/25 | 2.08 | 2.16 | 2.04 | 2.10 | 41,500 |
|
|
||||
|
|
||||
|
|